Flux through multicellular layers of a technetium-99m-nitroimidazole for imaging hypoxia

Cancer Biotherapy and Radiopharmaceuticals

Volumn 17, Issue 5, 2002, Pages 515-526

  Melo, Tricia ^a   Tunggal, Jonathan K ^a   Ballinger, James R ^b   Rauth, A Michael ^a  

^a Departments of Medical Biophysics   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

2 nitroimidazole; BRU59 21; Diagnosis; Hypoxia; Multicellular layer

Indexed keywords

2 NITROIMIDAZOLE DERIVATIVE; BRU 59; BRU 59 21; OXO[(3,3,9,9 TETRAMETHYL 5 OXA 4,8 DIAZAUNDECANE 2,10 DIONEDIOXIMATO) 3 N,N',N'',N''']TECHNETIUM TC 99M; OXO[3,3,9,9 TETRAMETHYL 1 (2 NITRO 1H IMIDAZOL 1 YL) 4,8 DIAZAUNDECANE 2,10 DIONEDIOXIMATO]TECHNETIUM TC 99M; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DIFFUSION; DRUG METABOLISM; DRUG STRUCTURE; DRUG UPTAKE; HAMSTER; HUMAN; HYPOXIA; ISOTOPE LABELING; METABOLITE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; SOLID TUMOR;

EID: 0036028902     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497802760804745     Document Type: Article

References (28)

1. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509.
2. Nordsmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 2000;57:39.
3. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285.
4. Fyles AW, Milosevic M, Wong R, Kavanagh M-C, Pintilie M, Sun A, Chapman W, Levin W, Manchul L, Keane TJ, Hill RP. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;48:149.
5. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941.
6. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88.
7. Sundfor K, Lyng H, Rofstad EK. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br J Cancer 1998;78:822.
8. Rockwell S, Yuan J, Peretz S, Glazer PM. Genomic instability in cancer. Novartis Found Symp 2001;240:133.
9. Hockel M, Vaupel P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266.
10. Stone HB, Brown JM, Phillips TL, Sutherland RM. Oxygen in human tumors: Correlations between methods of measurement and response to therapy. Radiat Res 1993;136:422.
11. Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 1998;46:229.
12. Ballinger JR. Imaging hypoxia in tumors. Semin Nucl Med 2001;31:321.
13. Koh W-J, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, Krohn KA, Griffen TW. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992;22:199.
14. Raleigh JA, Dewhirst MW, Thrall DE. Measuring tumor hypoxia. Semin Radiat Oncol 1996;6:37.
15. Koh W-J, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, Grierson JR, Lindsley KL, Lewellen TK, Krohn KA, Griffen TW. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Onocol Biol Phys 1995;33:391.
16. Linder KE, Chan Y-W, Cyr JE, Malley MF, Nowotnik DP, Nunn AD. TcO(PnAO-1-(2-nitroimidazole)) [BMS181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: Synthesis, characterization and xanthine oxidase-catalyzed reduction. J Med Chem 1994;37:9.
17. Wedeking P, Yost F, Wen M, Patel B, Eaton S, Romero V, Linder KE. Comparison of the biologic activity of the isomers of the Tc-99m-nitroimidazole complex BMS 194796 [Abstract]. J Nucl Med 1995;36:17P.
18. Ballinger JR, Kee JW, Rauth AM. In vitro and in vivo evaluation of a technetium-99m-labelled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. J Nucl Med 1996;37:1023.
19. Melo T, Duncan J, Ballinger JR, Rauth AM. BRU5921, a second-generation technetium-99m-labeled 2-nitroimidazole for imaging hypoxia in tumors. J Nucl Med 2000;41:169.
20. Barron B, Grotta J, Lamki L, Villar C, Ephron V, Patel D. Preliminary experience with technetium-99m BMS-181321, a nitroimidazole, in the detection of cerebral ischemia associated with acute stroke [Abstract]. J Nucl Med 1996;37:272P.
21. Cowan DSM, Hicks KO, Wilson WR. Multicellular membranes as an in vitro model for extravascular diffusion in tumors. Br J Cancer 1996;74(Suppl 27):S28.
22. Hicks KO, Ohms SJ, van Zijl PL, Denny WA, Hunter PJ, Wilson WR. An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours. Br J Cancer 1997;76:894.
23. Melo T, Ballinger JR, Rauth AM. The role of NADPH:cytochrome P450 reductase in the hypoxic accumulation and metabolism of BRU59-21, a technetium-99m-nitroimidazole for imaging hypoxia. Biochem Pharmacol 2000;60:625.
24. Zhang X, Melo T, Rauth AM, Ballinger JR. Cellular accumulation and retention of the technetium-99m-labelled hypoxia markers BRU59-21 and butylene amine oxime. Nucl Med Biol 2001;28;949.
25. Pirro JP, Di Rocco RJ, Narra RK, Nunn AD. Relationship between in vitro transendothelial permeability and in vivo single-pass brain extraction. J Nucl Med 1994;35:1514.
26. Hicks KO, Fleming Y, Siim BG, Koch CJ, Wilson WR. Extravascular diffusion of tirapazamine: Effect of metabolic consumption assessed using the multicellular layer model. Int J Radiat Oncol Biol Phys 1998;42:641.
27. Melo T, Hua HA, Ballinger JR, Rauth AM. Modifying the in vitro accumulation of BMS181321, a technetium-99m-nitroimidazole, with unlabelled nitroaromatics. Biochem Pharmacol 1997;54:685.
28. McClelland RA, Panicucci R, Rauth AM. Products of the reductions of 2-nitroimidazoles. J Am Chem Soc 1987;109:4308.